Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
WON TECH Co.,Ltd. (336570.KQ)
Daejeon, KR
WON TECH Co.,Ltd. is a global manufacturer and supplier of sophisticated laser and energy-based medical devices. The company's extensive portfolio caters to diverse applications, including aesthetic enhancements, comprehensive skincare, home-use solutions, and specialized surgical interventions. These innovative technologies facilitate a broad spectrum of treatments, such as non-invasive facial lifting and skin tightening, body sculpting, overall skin revitalization, efficient tattoo and scar removal, addressing stretch marks and vascular concerns, permanent hair reduction, and various surgical procedures. Founded in 1999, the enterprise was initially known as WONTECHnology, formally adopting the name WON TECH Co.,Ltd. in 2013. Its main office is situated in Daejeon, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.13% | -12.16% | +9.56% | +3.62% | +5.39% | -2.79% | -13.76% | +1.52% | +241.28% | +300.00% | +300.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+36.1% ★ Q1'26: +7.6% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+20.2% ★ Q1'26: -12.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+26.4% ★ Q1'26: -19.3% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+31.0% ★ Q1'26: +27.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+53.7% ★ Q1'26: +44.4% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+1.0% Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.38× ★ Q1'26: 0.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
115.63B
est: 119.09B (-2.9%)
|
115.25B
est: 111.74B (+3.1%)
|
156.84B
est: 157.92B (-0.7%)
|
193.53B
185.39B – 200.60B
+22.6% YoY
|
228.13B
188.63B – 253.96B
+17.9% YoY
|
278.67B
247.32B – 300.32B
+22.2% YoY
|
| EBITDA |
50.31B
est: 54.65B (-8.0%)
|
43.34B
est: 36.27B (+19.5%)
|
51.47B
est: 51.26B (+0.4%)
|
62.81B
60.17B – 65.11B
+22.6% YoY
|
74.04B
61.22B – 82.43B
+17.9% YoY
|
90.45B
80.27B – 97.47B
+22.2% YoY
|
| EBIT |
48.47B
est: 52.34B (-7.4%)
|
40.93B
est: 33.68B (+21.5%)
|
48.56B
est: 47.61B (+2.0%)
|
58.34B
55.89B – 60.47B
+22.6% YoY
|
68.77B
56.86B – 76.56B
+17.9% YoY
|
84.01B
74.56B – 90.53B
+22.2% YoY
|
| Net Income |
38.83B
est: 39.06B (-0.6%)
|
29.11B
est: 24.67B (+18.0%)
|
35.22B
est: 43.91B (-19.8%)
|
47.23B
42.19B – 52.28B
+7.6% YoY
|
57.94B
45.92B – 68.80B
+22.7% YoY
|
72.19B
61.63B – 79.48B
+24.6% YoY
|
| SGA |
16.04B
est: 49.48B (-67.6%)
|
22.61B
est: 24.65B (-8.3%)
|
33.54B
est: 34.83B (-3.7%)
|
42.69B
40.89B – 44.25B
+22.6% YoY
|
50.32B
41.61B – 56.02B
+17.9% YoY
|
61.47B
54.55B – 66.24B
+22.2% YoY
|
| EPS |
441.00
est: 438.33 (+0.6%)
|
326.71
est: 274.19 (+19.2%)
|
392.80
est: 488.01 (-19.5%)
|
525.00
468.95 – 581.05
+7.6% YoY
|
644.00
510.40 – 764.69
+22.7% YoY
|
802.33
685.01 – 883.37
+24.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jung-hyun Kim | CEO & Inside Director | 1B | male |
| Han-gu Lee | Chief Financial Officer | — | male |
| Jeong-yoon Choi | C. P. O. | — | female |
| Jongwon Kim | CEO & Chairman | — | male |
| Young-seok Seo | CTO & Inside Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 336570.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
